More than 1.6 million children and teens in the U.S. with peanut allergy deal with the serious and potentially life-threatening consequences of accidental exposure to peanuts on a daily basis. Even foods that don’t contain peanuts may be contaminated in the manufacturing process, making complete avoidance a challenge.
Earlier this year, the U.S. FDA approved the first oral immunotherapy (OIT) for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut in patients aged 4 through 17 years. OIT is a medical therapy that aims to desensitize the individual by gradually introducing increasing amounts of the allergenic protein of the problem food to reduce the risk of severe allergic reactions.
Learn more and find a provider here.